Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

The primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with pembrolizumab every six weeks (Q6W).

Official Title

A Phase 2 Study of Pembrolizumab (MK-3475) Every 6 Weeks (Q6W) in Participants With Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)

Keywords

Hodgkin's Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), PD1, PD-1, PDL1, PD-L1, Lymphoma, B-Cell Lymphoma, Hodgkin Disease, Pembrolizumab

Eligibility

Locations

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site
    Torrance California 90502 United States
  • Cross Cancer Institute ( Site 0207)
    Edmonton Alberta T6G 1Z2 Canada

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Merck Sharp & Dohme LLC
Links
Merck Clinical Trials Information Plain Language Summary
ID
NCT04875195
Phase
Phase 2 research study
Study Type
Interventional
Participants
About 66 people participating
Last Updated